anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Accelerated partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm PTV margin. Treatment duration will be 5-6 days and treatments will be on alternative weekdays, with a minimum interval of 40 hours between subsequent fractions.
After preoxygenation, intravenous fentanyl (1 μg/kg), propofol (2 mg/kg), and rocuronium (0.6 mg/kg) will be used for anesthesia induction. Intubation will be performed with a 7.0-8.0 sized tube, followed by the initiation of mechanical ventilation (tidal volume: 6-8 ml/kg, respiratory rate: 12 breaths/min). Sevoflurane will be used to maintain anesthesia (0.7-1 MAC), and remifentanil infusion will be administered for analgesia. Postoperatively, tramadol (1 mg/kg) and paracetamol (10 mg/kg) will be administered intravenously. Neuromuscular blockade will be reversed using sugammadex. Patients with an Aldrete Recovery Score ≥9 will be transferred to the post-anesthesia care unit after extubation.
Patients receive placebo PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
Composition for treating tinnitus comprises an antiinflammatory agent and an anticonvulsant. ACTIVITY : Auditory; Antiinflammatory; Anticonvulsant; Tranquilizer. Patients with tinnitus were treated with a tablet containing ibuprofen (400 mg) at 20:00 hours, a tablet containing ketoprofen (150 mg) at 21:00 hours, and a tablet containing clonazepam (1 mg) and a tablet containing doxylamine succinate (7.5 mg) at 21:30. This caused the patients to fall asleep at about 22:30. Sleep was profound and lasted 8 hours or more. An improvement in symptoms was observed from the next morning, generally lasting until the evening. MECHANISM OF ACTION : None given.
Non-pharmaceutical personal protective (NPP) measures such as face masks use, and hand and respiratory hygiene can be effective measures for mitigating the spread of aerosol/airborne diseases, such as COVID-19, in the absence of vaccination or treatment. However, the usage of such measures is constrained by their inherent perceived cost and effectiveness for reducing transmission risk. To understand the complex interaction of disease dynamics and individuals decision whether to adopt NPP or not, we incorporate evolutionary game theory into an epidemic model such as COVID-19. To compare how self-interested NPP use differs from social optimum, we also investigated optional control from a central planner's perspective. We use Pontryagin's maximum principle to identify the population-level NPP uptake that minimizes disease incidence by incurring the minimum costs. The evolutionary behavior model shows that NPP uptake increases at lower perceived costs of NPP, higher transmission risk, shorter duration of NPP use, higher effectiveness of NPP, and shorter duration of disease-induced immunity. Though social optimum NPP usage is generally more effective in reducing disease incidence than self-interested usage, our analysis identifies conditions under which both strategies get closer. Our model provides new insights for public health in mitigating a disease outbreak through NPP.
2130453 9317117 PCTABS00025 Heterologous polypeptides are produced in Lactococcus by means of a T7 or T7-like RNA polymerase gene placed under the control of an inducible promoter effective in the Lactococcal host, and a promoter specific for said polymerase upstream of a coding sequence for the desired polypeptide, whereby the promoter directs transcription of said coding sequence selectively as a result of expression of said polymerase. Surprisingly, the Gram-negative E. coli) derived T7 RNA polymerase system works extremely well in the Gram-positive Lactococcus host. The heterologous polypeptide can be produced in high yields (e.g. 22%) as soluble intracellular protein, or can be secreted, e.g. at a rate commensurate with its expression so that only low levels or zero amount of polypeptide is accumulated intracellularly. The polypeptide within the cell, being biologically active, can be delivered in that encapsulated form, e.g. as a parenteral, topical or oral medicament or vaccine, or as an environmental pesticide. Examples of expression product are TTFC, the HIV V3 loop and B. thuringiensis toxins.
OBJECTIVES: Cardiac diastolic dysfunction (left ventricular diastolic dysfunction [LVDD]) is a well-known predictor of heart failure. We hypothesized that sarcopenia is independently associated with diastolic dysfunction. We aimed to investigate the association of the most recent consensus definition of sarcopenia with LVDD.
METHODS: We included 121 older participants admitted to a cardiology outpatient clinic. We followed the European Working Group on Sarcopenia in Older People 2 definition of confirmed sarcopenia (presence of low muscle mass and low muscle strength). We estimated skeletal muscle mass with bioimpedance analysis and muscle strength by hand grip strength via a Jamar hydraulic hand dynamometer. Skeletal muscle mass was adjusted by body mass index. LVDD was determined by echocardiographic parameters measured per American Society of Echocardiography recommendations. We ran multivariate logistic regression analyses adjusted for well-known risk factors for diastolic dysfunction (i.e., age, sex, obesity, smoking, diabetes mellitus, hypertension, and ischemic heart disease) to detect whether sarcopenia was independently associated with diastolic dysfunction. We gave results in odds ratio (OR) and 95% confidence interval (CI).
RESULTS: Mean age was 69.9 ± 5.8 years, and 38.8% of participants were male. Confirmed sarcopenia was detected in 34.7%, and diastolic dysfunction was detected in 19.8%. In univariate analyses, sarcopenia was associated with diastolic dysfunction (OR, 6.7, 95% CI, 2.4-18.9). Regression analyses showed that two parameters, sarcopenia (OR, 7.4, 95% CI, 2.1-26.6, P = 0.002) and obesity (OR, 5.0, 95% CI, 1.03-24.6, P = 0.046), were associated with diastolic dysfunction.
CONCLUSIONS: This study revealed sarcopenia to be a new risk factor for diastolic dysfunction, adding to its known risk factors. Future longitudinal studies are needed to clarify the factors underlying their copresence.
BACKGROUND: The high risk of major adverse cardiovascular events (MACE) in patients with chronic kidney disease (CKD) has been well described. However, the efficacy of fibrates on the risk of MACE in patients with CKD remains unclear.
METHODS: We conducted a nested case-control study using data from a large administrative database that included more than 1.5 million Japanese patients. We defined cases as CKD patients with incidences of MACE and matched them with controls based on age, sex, calendar year of cohort entry and CKD stage. Fibrate exposure timing was categorized as current, recent or past. A conditional logistic regression analysis was used to investigate the association between fibrate use and the risk of MACE.
RESULTS: Our study included 47 490 patients with CKD, with 15 830 MACE identified during a median follow-up of 9.4 months. The numbers of fibrates used during the study period were 556 (3.5%) in the case group and 1109 (3.5%) in the control group. Fibrate use was significantly associated with a decreased risk of MACE [odds ratio (OR) 0.84; 95% confidence interval (CI) 0.75-0.94], particularly for current (OR 0.81; 95% CI 0.68-0.97) and recent use (OR 0.65; 95% CI 0.48-0.90). Regarding the class effect of fibrates, pemafibrate use, but not bezafibrate or fenofibrate use, was significantly associated with a decreased risk of MACE (OR 0.73; 95% CI 0.528-0.997).
CONCLUSION: Recent and current fibrate use, especially pemafibrate use, was associated with a reduced risk of MACE in patients with CKD. This suggests the potential benefits of continuous fibrate therapy and the possible superiority of pemafibrate over other fibrates. However, further investigations in different populations are required to confirm the generalizability of these findings.
FIELD: medicine, in particular, medical cosmetology. SUBSTANCE: cream containing natural bee wax, stabilizer, fat and water phases, additionally has extract of drone larvae. Used as a stabilizer is concentrate of biologically active components of isoprenoid and phenylpropanoid row separated from propolis at the following ratio of components, mas.%: natural bee wax, 2-15; extract of drone larvae, 1-5; concentrate of biologically active components separated from propolis, 0.1-3.0; fat phase, 40-60; water phase, the balance. Used as fat phase are natural vegetable and/or animal oils. Cream improves fat metabolism in tissues and is recommended for middle-aged persons and also for persons with presenilation of integument. EFFECT: higher efficiency. 2 cl
Hepatosplenic T-cell lymphoma has been reported in patients treated with mercaptopurine for inflammatory bowel disease (IBD), an unapproved use. Mercaptopurine is mutagenic in animals and humans, carcinogenic in animals, and may increase the risk of secondary malignancies.

Patients receiving immunosuppressive therapy, including mercaptopurine, are at an increased risk of developing lymphoproliferative disorders and other malignancies, notably skin cancers (melanoma and non-melanoma), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ. The increased risk appears to be related to the degree and duration of immunosuppression. It has been reported that discontinuation of immunosuppression may provide partial regression of the lymphoproliferative disorder.

A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. A combination of multiple immunosuppressants, given concomitantly increases the risk of Epstein-Barr virus (EBV)-associated lymphoproliferative disorders.
Sexually transmitted infections (STIs) continue to be a health concern in the United States, particularly in rural settings. Point-of-care (POC) STI testing is useful in overcoming access barriers in these settings. The purpose of this project was to implement POC STI testing to increase access to care in rural settings and test the feasibility of this model. Six mobile health clinics were implemented by a nurse-led team in three rural communities in the Blackbelt region of Alabama utilizing the Binx IO® to test for chlamydia and gonorrhea. Mobile clinic volunteers participated in focus groups to determine provider satisfaction with clinic workflow. The mobile health clinics were a feasible way to increase access to STI testing in rural settings with reported provider and client satisfaction in work flow.
Nausea and nomiting of Pregnancy (NVP) affects up to 80% of pregnant women . Severe NVP is one of the most common indications for hospital admission among pregnant women, with typical stays of between 3 and 4 days . Onset of NVP is in the first trimester. It typically starts between the fourth and seventh weeks of gestation, peaks in approximately the ninth week and resolves by the 20th week in 90% of women. If the initial onset is after 10+6 weeks of gestation, other causes need to be considered There is a broad spectrum of nausea and vomiting of pregnancy (NVP) severity, ranging from mild, occasional nausea to severe, intractable vomiting requiring hospitalisation (hyperemesis gravidarum). Hyperemesis gravidarum(HG) is defined severe, protracted nausea and vomiting associated with weight loss of more than 5% of prepregnancy weight, dehydration and electrolyte imbalances. The exact underlying pathophysiology is unknown, but etiology is believed to be multifactorial, including endocrine, gastrointestinal and environmental factors.5 Risk factors include lower maternal age, primigravidity, lower socioeconomic background and non-smoking status.

Admission for hyperemesis gravidarum depends on clinical impression by the attending or referring physician. There is a need for classification the severity of NVP to restrict admission to those who need admission. An objective and validated index of nausea and vomiting such as the Pregnancy-Unique Quantification of Emesis (PUQE) score may be used for this purpose.

This questionnaire contains three questions regarding the time-span of nausea, vomiting and retching respectively, as well as one question assessing the global psychological and physical quality of life (QOL). Initially the questionnaire evaluated symptoms during last 12 hours, but it has been modified to encompass 24 hours as well as the whole of first trimester of pregnancy The PUQE questionnaire was used in several studies to assess the effect of antiemetic treatments for emesis and hyperemesis . In this study, the role of PUQE in evaluating need for inpatient admission will be studied. Also, the response to treatment inside the hospital will be assessed
The present invention is a metallic gel nail polish composition and method of application. The polish lacks harmful airborne toxins and is comprised of monomers, aluminum, epoxy acrylate oligomer, acrylic acid polymer and photoinitiator. The aluminum is deduced to a semi-solid phase before mixing in with the remaining chemicals. When the composition is applied to a solid surface, the surface tension between the aluminum and remaining chemicals disperses the aluminum evenly across a surface resulting in a shiny, metallic color. The composition is cured for about 2 minutes using an about 36-watt UV light or about 10-60 seconds using an LED light. The composition may be applied above a cured standard base coat or under a cured standard top coat. If a colored metallic color is desired, a translucent gel polish is applied atop the cured metallic gel polish whereby the aluminum particles reflect off the translucent coat.
Cardiac Electrophysiology

FARYDAK may prolong cardiac ventricular repolarization (QT interval) [see Warnings and Precautions (5.2)]. In the randomized multiple myeloma trial, QTc prolongation with values between 451 msec to 480 msec occurred in 10.8% of FARYDAK treated patients. Events with values of 481 msec to 500 msec occurred in 1.3% of FARYDAK treated patients. A maximum QTcF increase from baseline of between 31 msec and 60 msec was reported in 14.5% of FARYDAK treated patients. A maximum QTcF increase from baseline of >60 msec was reported in 0.8% of FARYDAK treated patients. No episodes of QTcF prolongation >500 msec have been reported with the dose of 20 mg FARYDAK in the randomized multiple myeloma trial conducted in combination with bortezomib and dexamethasone. Pooled clinical data from over 500 patients treated with single agent FARYDAK in multiple indications and at different dose levels has shown that the incidence of CTC Grade 3 QTc prolongation (QTcF >500 msec) was approximately 1% overall and 5% or more at a dose of 60 mg or higher.
The invention discloses an anti-pIgR nano antibody and application thereof, wherein the nano antibody is PI-19, PI-21, PI-28, PI-5 and PI-74, and the amino acid sequences of the nano antibody are respectively shown in SEQ ID NO: 10. SEQ ID NO: 3. SEQ ID NO: 2. SEQ ID NO:13 and SEQ ID NO: shown at 27. The invention screens by utilizing phage display library to obtain the nano antibody capable of combining with pIgR with high affinity. The nano-antibody against pIgR obtained by screening in the invention binds pIgR with high affinity, can be used for preparing medicines for treating diseases related to pIgR, and provides a new means for treating the diseases.
A coating for masking or reducing the detectable presence of certain characteristic odor or odors, taste or tastes of pharmaceutical preparations, particularly valerian extracts, is described. The coating comprises from at least one to three coating compartments, in any combination or as a singlelayer amalgam. The first coating compartment (4) preferably comprises a hydroxyalkyl cellulose and an antitackiness agent. The second coating compartment (6) preferably comprises a sugar and at least one antitackiness agent. The third coating compartment (8) preferably comprises a methacrylate copolymer, a hydroxyalkyl cellulose and an antitackiness agent. An option fourth coating compartment (10) may be applied as a cosmetic color coat, need not function as an odormasking coat, and may be combined with one or more of the other three coating compartments.
Hair care compositions containing a synergistic mixture of three anti-free-radical agents selected from (a) ascorbic acid, its salts and esters; (b) tocopherol and its esters, such as tocopherol acetate; and (c) herbal extracts selected from morus alba, origanum vulgare, panax ginseng, rosmarinus officinalis, camellia sinensis and grape seed extract in a suitable diluent or carrier. Preferred synergistic mixtures are Origanum vulgare, sodium ascorbyl phosphate and morus alba. Origanum vulgare, sodium ascorbyl phosphate and panax ginseng. Panax ginseng, morus alba and Origanum vulgare. Sodium ascorbyl phosphate, morus alba and camellia sinensis. Sodium ascorbyl phosphate, morus alba and grape seed Origanum vulgare, panax ginseng and rosmarinus officinalis.
<P>PROBLEM TO BE SOLVED: To easily and accurately set the aggregate of images consisting of image data selected from a number of image data.  <P>SOLUTION: An image data memory part 22 stores the image data on an object of diagnosis supplied from a medical image diagnosis apparatus 25, etc. and their supplementary information. A supplementary information managing list preparing part 21 hierarchically classifies the supplementary information read from the image data memory part 22 and prepares a supplementary information managing list. A conditional expression setting part 11 prepares a conditional expression for the aggregate of images for setting a desired aggregate of images based on the supplementary information on the supplementary information managing list. Then, a search engine part 12, having received the conditional expression for the aggregate of images via a process application part 13, reads image data constituting the aggregate of images from the image data memory part 22 based on the conditional expression for the aggregate of images, and feeds the obtained aggregate of images consisting of image data to the process application part 13 to execute a desired image data processing.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Patients will be given IV fluids and premedication with 500 mg metronidazole, 10 mg dexamethasone, and 8 mg ondansetron to prevent infection, limit pain and nausea. The femoral artery will be accessed and a catheter advanced into the superior mesenteric artery. Positioning of all catheters will be confirmed by injection of radiographic contrast material. Superior mesenteric angiography will be performed with images obtained through the portal venous phase to confirm patency and flow direction of the portal vein and determine the presence of aberrant supply to the right lobe of the liver by the superior mesenteric artery. The catheter will then be advanced into the celiac artery. Celiac angiography will be performed to determine remainder of the hepatic arterial anatomy. Selection of the tumor bearing artery will then be performed with a microcatheter which is advanced through the catheter in the celiac artery origin. Selection will be guided by fluoroscopy and will be at the lobar level or peripherally in all cases. Once the feeding vessel has been selected and confirmed by contrast injection, the physician will initiate embolization with LC Beads. Up to two vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared. The LC Beads will be mixed with radiographic contrast to ensure fluoroscopic visibility during injection. Under careful fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery reaches stasis prior to administration of both vials, the residual volume of LC Beads will be noted on the surgical report form. If after administration of the DEB, there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization. After confirming that the artery is appropriately treated, all catheters and guidewires will be removed from the femoral artery and hemostasis obtained.
Most pharmacologic treatments of depression rely on serotonergic and/or noradrenergic mechanisms. Yet, evidence both from animal studies and from human trials suggests a role for dopaminergic pathways and particularly for dopamine D2-like receptors in the treatment of depression. In recent years, two new selective agonists of dopamine D2-like receptors have come into clinical use for the treatment of parkinsonism. Preliminary evidence suggests that these drugs might be useful as antidepressants. We are testing whether one of these agonists, ropinirole, is an effective augmentation strategy in depressed patients in a double-blind, randomized, controlled trial. We are recruiting unipolar and bipolar patients who remained depressed (modified Hamilton Depression Rating Scale score greater than 16) despite at least 4 weeks of treatment with an adequate dose of antidepressant medication. Patients receive either 2mg of oral ropinirole or placebo twice daily added on to their current medication and are evaluated weekly over 7 weeks and are assessed weekly using two depression rating scales.
The arm includes all the villages under study. Health education will be provided targeting following groups: 1. Home makers 2. School children 3. Water tank operators.
An apparatus includes a first member coupled to a second member. The first member defines a chamber containing a dry powder and includes a chamber wall that forms an outer boundary of the chamber. The second member includes a surface covering the chamber and defines an intake channel and an exit channel The exit channel is fluidically coupled to the chamber via an exit opening. The intake channel is fluidically coupled to the chamber via an intake port. A center line of the intake channel is tangential to a portion of the chamber wall such that a portion of an inlet airflow conveyed into the chamber via the intake channel has a rotational motion. The intake port is defined at least in part by an intake ramp. The intake ramp includes a transition surface that forms an exit angle with respect to the surface of less than 105 degrees.
PURPOSE: To obtain a water-based manicure, improved in water resistance, capable of stably dispersing an inorganic powder therein without causing the caking even in the case of settling, readily redispersing the pigment and excellent in usability by coating and treating the surface of the inorganic powder with a water and oil repellent and blending the resultant pigment therein. CONSTITUTION: This water-based manicure is obtained by blending an inorganic pigment treated by coating with a water and oil repellent and excellent in redispersibility of the inorganic pigment and usability. The inorganic pigment is prepared by carrying out the sticking treatment or chemical binding treatment of the surface of the inorganic pigment with the water and oil repellent. In the case of the sticking treatment, e.g. a compound having a fluoroalkyl group (e.g. a perfluoro polyether) can preferably be used. In the case of the chemical binding treatment, e.g. a fluorosilane, etc., such as a perfluoroalkylsilane can suitably be used. For example, talc, kaolin, sericite, mica or titanium-treated mica can be used as the inorganic pigment. The water-based manicure is preferably blended with 0.1-10wt.%, especially 0.2-4.0wt.% inorganic pigment.